American Century Companies Inc. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 591,617 shares of the company’s stock after selling 239,230 shares during the quarter. American Century Companies Inc. owned 0.68% of IDEXX Laboratories worth $147,703,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of IDXX. Allianz Asset Management GmbH boosted its stake in shares of IDEXX Laboratories by 11.9% in the 1st quarter. Allianz Asset Management GmbH now owns 81,713 shares of the company’s stock valued at $15,639,000 after purchasing an additional 8,664 shares in the last quarter. IFM Investors Pty Ltd boosted its stake in shares of IDEXX Laboratories by 50.0% in the 2nd quarter. IFM Investors Pty Ltd now owns 3,871 shares of the company’s stock valued at $844,000 after purchasing an additional 1,291 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in shares of IDEXX Laboratories by 21.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 19,335 shares of the company’s stock valued at $4,213,000 after purchasing an additional 3,460 shares in the last quarter. First Citizens Bank & Trust Co. purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $888,000. Finally, Daiwa SB Investments Ltd. boosted its stake in shares of IDEXX Laboratories by 21.9% in the 2nd quarter. Daiwa SB Investments Ltd. now owns 4,390 shares of the company’s stock valued at $957,000 after purchasing an additional 790 shares in the last quarter. Hedge funds and other institutional investors own 91.27% of the company’s stock.
In related news, insider Michael Lane sold 5,912 shares of the company’s stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $243.78, for a total transaction of $1,441,227.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jonathan W. Ayers sold 7,000 shares of the company’s stock in a transaction on Thursday, August 23rd. The shares were sold at an average price of $247.33, for a total transaction of $1,731,310.00. The disclosure for this sale can be found here. Insiders have sold a total of 64,844 shares of company stock valued at $15,742,129 over the last quarter. 2.56% of the stock is currently owned by company insiders.
Shares of IDEXX Laboratories stock opened at $207.17 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $146.09 and a 52-week high of $256.22. The firm has a market capitalization of $17.44 billion, a PE ratio of 63.16, a price-to-earnings-growth ratio of 2.57 and a beta of 0.82.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, November 1st. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. IDEXX Laboratories had a net margin of 15.19% and a negative return on equity of 994.76%. The company had revenue of $545.00 million during the quarter, compared to analyst estimates of $545.66 million. During the same period in the prior year, the business posted $0.76 EPS. The firm’s revenue was up 10.8% compared to the same quarter last year. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 4.19 earnings per share for the current fiscal year.
A number of equities research analysts have recently issued reports on IDXX shares. BidaskClub cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 11th. Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, August 6th. Credit Suisse Group upped their price objective on shares of IDEXX Laboratories from $255.00 to $259.00 and gave the company an “outperform” rating in a research note on Friday, August 17th. Piper Jaffray Companies upped their price objective on shares of IDEXX Laboratories to $236.00 and gave the company an “overweight” rating in a research note on Wednesday, August 1st. Finally, Bank of America cut their price objective on shares of IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, November 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. IDEXX Laboratories currently has a consensus rating of “Buy” and a consensus target price of $252.33.
COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/11/10/american-century-companies-inc-has-147-70-million-position-in-idexx-laboratories-inc-idxx.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.